Cargando…

Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2

Detalles Bibliográficos
Autores principales:	Grundschober, E, Hoelbl-Kovacic, A, Bhagwat, N, Kovacic, B, Scheicher, R, Eckelhart, E, Kollmann, K, Keller, M, Grebien, F, Wagner, K-U, Levine, R L, Sexl, V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158830/ https://www.ncbi.nlm.nih.gov/pubmed/24791858 http://dx.doi.org/10.1038/leu.2014.152

Ejemplares similares

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
por: Warsch, Wolfgang, et al.
Publicado: (2012)

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
por: Hoelbl, Andrea, et al.
Publicado: (2010)

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis
por: Berger, A, et al.
Publicado: (2014)

Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia
por: Kollmann, Sebastian, et al.
Publicado: (2019)

Expansion of BCR/ABL1 (+) cells requires PAK2 but not PAK1
por: Edlinger, Leo, et al.
Publicado: (2017)

Evaluation of Stat5 as a potential drug target in bcr/abl-induced leukemias
por: Hölbl, Andrea, et al.
Publicado: (2008)

A kinase-independent role for CDK8 in BCR-ABL1(+) leukemia
por: Menzl, Ingeborg, et al.
Publicado: (2019)

P1310: A ROBUST APPROACH FOR THE GENERATION OF FUNCTIONAL HEMATOPOIETIC PROGENITOR CELL LINES TO MODEL LEUKEMIC TRANSFORMATION
por: Doma, E., et al.
Publicado: (2022)

STAT5A and STAT5B—Twins with Different Personalities in Hematopoiesis and Leukemia
por: Maurer, Barbara, et al.
Publicado: (2019)

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
por: Grebien, Florian, et al.
Publicado: (2011)

Isolation, Maintenance and Expansion of Adult Hematopoietic Stem/Progenitor Cells and Leukemic Stem Cells
por: Mayer, Isabella Maria, et al.
Publicado: (2022)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

Deletion of ABL/BCR on der(9) associated with severe basophilia
por: Vaidya, Shantashri, et al.
Publicado: (2011)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
por: Wei, Liuya, et al.
Publicado: (2020)

Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
por: Berger, Angelika, et al.
Publicado: (2014)

Loss of Gadd45b accelerates BCR-ABL-driven CML
por: Sha, Xiaojin, et al.
Publicado: (2018)

SOX6 blocks the proliferation of BCR-ABL1(+) and JAK2V617F(+) leukemic cells
por: Barbarani, Gloria, et al.
Publicado: (2019)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Philadelphia Chromosome‐positive Chronic Myelogenous Leukemia with Deleted Fusion of BCR and ABL Genes
por: Ohyashiki, Kazuma, et al.
Publicado: (1990)

Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells
por: Al-Rawashde, Futoon Abedrabbu, et al.
Publicado: (2021)

Opioids: Modulators of angiogenesis in wound healing and cancer
por: Ondrovics, Martina, et al.
Publicado: (2017)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
por: Zhou, A, et al.
Publicado: (2015)

BCR‐ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia
Publicado: (2019)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

JAK2阳性慢性髓性白血病合并疑似BCR-ABL变异型一例
Publicado: (2018)

The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis
por: Mian, Afsar A., et al.
Publicado: (2019)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia
por: Mukherjee, Kaushiki, et al.
Publicado: (2017)

Inflammation accelerates BCR-ABL1(+) B-ALL development through upregulation of AID
por: Zhang, Ping, et al.
Publicado: (2022)

Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera
por: Lorenzo, Mariana, et al.
Publicado: (2020)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

Persistence of chronic myelocytic leukemia despite deletion of rearranged bcr/c-abl sequences in blast crisis
Publicado: (1986)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tk6sep534etja1jecf173qui5j